Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider John Fesko sold 6,517 shares of the firm's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $321.53, for a total value of $2,095,411.01. Following the transaction, the insider directly owned 197,257 shares of the company's stock, valued at $63,424,043.21. This represents a 3.20% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
John Fesko also recently made the following trade(s):
- On Monday, August 3rd, John Fesko sold 295 shares of Natera stock. The stock was sold at an average price of $267.99, for a total transaction of $79,057.05.
- On Tuesday, July 28th, John Fesko sold 931 shares of Natera stock. The stock was sold at an average price of $254.07, for a total transaction of $236,539.17.
- On Monday, July 27th, John Fesko sold 782 shares of Natera stock. The shares were sold at an average price of $260.49, for a total transaction of $203,703.18.
Natera Price Performance
NASDAQ:NTRA traded down $12.44 during mid-day trading on Friday, hitting $326.26. 833,644 shares of the company's stock were exchanged, compared to its average volume of 1,496,455. The company has a market cap of $47.03 billion, a PE ratio of -239.90 and a beta of 1.51. Natera, Inc. has a one year low of $157.43 and a one year high of $343.18. The business has a fifty day moving average price of $285.07 and a 200 day moving average price of $233.61.
Natera (NASDAQ:NTRA - Get Free Report) last announced its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, beating analysts' consensus estimates of ($0.49) by $0.02. The business had revenue of $752.75 million during the quarter, compared to the consensus estimate of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The business's revenue for the quarter was up 37.7% on a year-over-year basis. During the same quarter last year, the firm earned ($0.74) earnings per share. On average, equities analysts forecast that Natera, Inc. will post -1.02 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of NTRA. California State Teachers Retirement System increased its holdings in Natera by 28,373.5% in the 2nd quarter. California State Teachers Retirement System now owns 56,324,789 shares of the medical research company's stock worth $15,289,364,000 after buying an additional 56,126,974 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Natera by 10.5% during the 4th quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company's stock valued at $2,944,800,000 after acquiring an additional 1,225,420 shares during the period. BlackRock Inc. purchased a new stake in shares of Natera during the 2nd quarter valued at about $2,962,770,000. Wellington Management Group LLP grew its stake in shares of Natera by 94.7% in the fourth quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company's stock worth $1,140,026,000 after acquiring an additional 2,420,263 shares during the period. Finally, State Street Corp grew its stake in shares of Natera by 2.2% in the third quarter. State Street Corp now owns 3,389,599 shares of the medical research company's stock worth $545,624,000 after acquiring an additional 72,087 shares during the period. Hedge funds and other institutional investors own 99.90% of the company's stock.
Wall Street Analyst Weigh In
A number of research firms have recently commented on NTRA. Leerink Partners set a $330.00 target price on Natera in a research note on Friday, August 7th. Royal Bank Of Canada upped their price target on shares of Natera from $275.00 to $350.00 and gave the stock an "outperform" rating in a research note on Friday, August 7th. Wolfe Research started coverage on shares of Natera in a research report on Tuesday, June 2nd. They set an "outperform" rating and a $260.00 price objective on the stock. Canaccord Genuity Group set a $375.00 price objective on shares of Natera in a research note on Friday, August 7th. Finally, TD Cowen lifted their target price on shares of Natera from $325.00 to $340.00 and gave the stock a "buy" rating in a report on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $319.38.
Get Our Latest Stock Analysis on NTRA
About Natera
(
Get Free Report)
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Natera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Natera wasn't on the list.
While Natera currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
